8 results about "Antagomir" patented technology

The invention relates to application of tsRNA-3025a as a prognostic marker of acute myocardial infarction and a treatment target spot of myocardial ischemia reperfusion injury. A DNA (Deoxyribonucleic Acid) sequence corresponding to the tsRNA-3025a is shown as SEQ ID NO: 1: 5 '-ATCCTGCCGACTACGCCA-3'. The tsRNA-3025a can be used for treating acute myocardial infarction and myocardial ischemia reperfusion injury. In the aspect of prognosis, a detection kit is provided, and the risk of heart failure and short-term adverse events of a patient is evaluated by quantitatively detecting the expression level of the tsRNA. In the aspect of treatment, the invention provides the application of the anti-tagomir for inhibiting the function or expression of tsRNA-3025a in the preparation of the medicine for treating the myocardial ischemia reperfusion injury, and the anti-tagomir is subjected to specific chemical modification. A novel biomarker is provided for prognosis risk stratification of acute myocardial infarction, and an effective treatment strategy is provided for prevention and treatment of myocardial ischemia-reperfusion injury.

The invention discloses an application and a preparation of a miR-125b-5p inhibitor or antagonist for treating and / or preventing myopia. According to the application, a miR-125b-5p inhibitor or antagonist, particularly miR-125b-5p antiagomir with a nucleotide sequence as shown in SEQ ID NO: 8, is used for inhibiting the expression of miR-125b-5p in sclera and increasing the expression of a target gene tp53, so that the transdifferentiation of sclera fibroblasts can be remarkably reduced, sclera remodeling can be reduced, and the diopter reduction and ocular axis extension of guinea pig deprivation myopia can be retarded; the composition can be used for preventing myopia and controlling myopia progress, has the advantages of low administration frequency and high safety, and provides a safer, more effective and more convenient prevention and control means for myopia patients, especially teenagers.

The invention belongs to the technical field of biology, and particularly relates to related tRF for detecting hypertrophic cardiomyopathy and a detection method and application thereof. The invention provides a marker for hypertrophic cardiomyopathy, the marker is CHAtRF, and the nucleotide sequence of the marker is as shown in SEQ ID NO: 1. The CHAtRF antisense nucleotide CHAtRF antiagomir can be used as an active ingredient in a product for treating hypertrophic cardiomyopathy. By using the CHAtRF antiagomir, the expression of CHAtRF in the heart can be inhibited, pathological myocardial hypertrophy can be remarkably inhibited, the fibrosis area can be reduced, and the effect of improving the heart function can be achieved, so that the purpose of preparing the medicine for preventing and / or treating hypertrophic cardiomyopathy by using the CHAtRF antiagomir as a novel gene therapy technology is achieved; and a new drug action target is provided for treatment of heart diseases related to hypertrophic cardiomyopathy.

The application discloses a kind of miR-335-3p antagomir rhubarb hydrogel and its preparation method and application, belong to medical technical field.The application is first with rhubarb, sodium alginate and crosslinking agent by self-assembly to form three-dimensional network structure, then miR-335-3p antagomir is loaded in three-dimensional network structure, obtains miR-335-3p antagomir rhubarb hydrogel.MiR-335-3p antagomir in miR-335-3p antagomir rhubarb hydrogel and rhubarb can exert synergistic effect, significantly reduce acute pancreatitis, curative effect is superior to single drug.Meanwhile, miR-335-3p antagomir rhubarb hydrogel can realize drug sustained-release function.In addition, the composition of miR-335-3p antagomir rhubarb hydrogel can realize in-vivo metabolism and is non-toxic, non-accumulation, and high safety.

The invention belongs to the technical field of biology, and particularly relates to related tRF for detecting myocardial ischemia injury and a detection method and application thereof. The invention provides a marker for myocardial ischemic injury, the marker is CIAtRF, and the nucleotide sequence of the CIAtRF is as shown in SEQ ID NO: 1. The expression of CIAtRF is up-regulated during myocardial injury, and CIAtRF participates in regulation and control of myocardial ischemic injury. The CIAtRF antiagomir provided by the invention can be used as an active ingredient in a product for treating myocardial ischemia reperfusion injury. By using the CIAtRF antiagomir, the expression of CIAtRF in the heart can be inhibited, the myocardial infarction area can be obviously inhibited, the fibrosis area can be reduced, and the survival rate of myocardial cells can be increased, so that myocardial ischemic injury is relieved, and the effect of improving the cardiac function is realized.

A method for sensitizing a cancer chemotherapy drug includes: transfecting a cancer cell with an antisense oligonucleotide (e.g., siRNA-1976 or antagomir-1976) to form a transgenic cancer cell, thereby blocking the subsequent effects of miR-1976; and applying a cancer composition to the transgenic cancer cell, at which point the transgenic cancer cell has been blocked from the subsequent effects of miR-1976, and because the transgenic cancer cell has been blocked from the subsequent effects of miR-1976, the transgenic cancer cell develops a sensitivity to the cancer composition.

A method of increasing sodium current in a cardiac cell generally includes introducing into the cardiac cell an miR-448 inhibitor in an amount effective to decrease miR-448 suppression of SCN5A mRNA transcription, thereby increasing sodium current in the cardiac cell. A method of increasing translation of SCN5A mRNA in a cell generally includes introducing into the cell an miR-448 inhibitor in an amount effective to decrease miR-448 suppression of SCN5A mRNA transcription. A method of decreasing arrythmia in a cardiac cell generally includes introducing into the cardiac cell an miR-448 inhibitor in an amount effective to decrease miR-448 suppression of SCN5A mRNA transcription. A method of treating arrythmia in a patient having, or at risk of having, arrythmia generally includes administering to the patient an miR-448 inhibitor in an amount effective to decrease the likelihood or extent of arrythmia in the patient. In some embodiments of all methods, the miR-448 inhibitor can be an miR-448 antagomir or an miR-448 sponge.